To assess the impact of database development on clinical practice and quality of care. METHODS: We chose the following aspects of patient care to be included in the database form: pre-surgery patient condition and medications, surgery information, recovery information, status of the patient atdischarge, 30-days and 365-days post-surgery follow-up information.Information was collected through structured questionnaire and entered into Microsoft Access software. RESULTS: From January 2006 -May 2011, there was 3418 open heart surgeries performed. The overall 30-daymortality was 3.6%. Post-surgery morbidity was 21.5%which includes 3.6% reoperation for bleeding 0.6% neurological 0.7% dialysis 1.3% heart failure 0.3% septicemia 1.8% prolonged ventilation 8.6% multiorgan failure and 0.9% respiratory complications 1.7% cardiac arrest,1.1% deep sternal wound infection 0.1% Follow up at30-days patients alive were 91.6% death 0.1% lost to follow-up 3.6%and 365-daysshowed that alive 93.2% death2.1% lost to followup,4.6%. CONCLUSIONS: Before this database, there was no way to monitor the risk factors, mortality and morbidity. Fortunately with the development of database, pre operation risk factors, post-surgery mortality and morbidity rates could easily be generated. Based on the prevalent risk factors coming up in our data we can help prevent the cardiac disease. It also helped in controlling preventable post-surgery complications. It also helps in identification of a gap inpatient knowledge regarding the use of warfarin after heart valve surgery and deficiencies in laboratory capabilities, both causing catastrophic complications. As a result, we modified our practice in an effort to address these issues and reduce the complication rates after heart valve surgery. Updated and stringently maintained database helps to identify deficiencies in practice and provides a direction for future improvement.
OBJECTIVES:
To investigate whether there is a relationship between the day of the week patients undergo elective surgery and in-hospital death. METHODS: Retrospective analysis of secondary users service data on adjusted odds ratios for inhospital death within 30 days of procedure using logistic regression modelling. Patients in acute and specialist English public hospitals undergoing elective surgery over the financial years 2006 to 2008. RESULTS: There were 15,230 in-hospital 30-day deaths as a consequence of 4,197,761 all elective inpatient surgical admissions (an overall crude mortality rate 3.6 per 1000). The overall adjusted odds of death for all elective surgical procedures were 33% and respectively 90% higher if the procedures were carried out on Friday or at Weekend compared to Monday (OR 1.33, 95% CI 1.26-1.41 and respectively OR 1.90, 95% CI 1.75-2.05). This equates to a figure of over 700 excess annual deaths from elective surgery, based on applying Monday mortality rates. CONCLUSIONS: The study suggests higher risk of death for patients who have elective surgical procedures carried out closer to the weekend, in particular on Friday. Further research is needed to understand the extent to which the 'weekday effect' reflects differences in the quality of surgical care. 
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PMH1 PHARMACOTHERAPY AND ASSOCIATED OUTCOMES IN PEDIATRIC BIPOLAR DEPRESSION
OBJECTIVES:
To examine medication utilization pattern among Medicaid enrolled children and adolescents with bipolar depression (BD). METHODS: Medicaid Analytic eXtract (MAX) data from New York, Illinois, California, and Texas, from 2003 to 2007 was used in the analysis. Bipolar depression patients were identified from inpatient and outpatient files by using ICD-9CM codes 296.5, 296.2, and 296.3. Utilization of selective serotonin reuptake inhibitors (SSRI) and other antidepressants, typical and atypical antipsychotics (SGA), and mood stabilizers (MS) (lithium, divalproex, oxcarbazepine etc) following a bipolar depression diagnosis was investigated. Prevalence of significant outcomes of the disease, namely depressive (ICD-9CM: 296.5, 296.2, 296.3) and manic (ICD-9CM: 296.0, 296.1, 296.4, 296.81) switch, and suicidality (ICD-9CM: E950-E958, V62.84) were also measured after initiation of pharmacotherapy treatment in the BD cohort. Descriptive analysis using SAS 9.2 was conducted to achieve the study objective. RESULTS: From descriptive analysis 23,113 children and adolescents aged 6-18 years and having a bipolar depression diagnosis were identified. The most commonly used psychotropic drugs following bipolar depression were SGA (76.45%), Mood stabilizer (66.05%), SSRI (48.71%), and other antidepressants (35.58%). The most commonly used psychotropic combinations were SGA-MS (40.40%), SGA-SSRI (12.20%), and SSRI-MS (6.04%). Suicidality was revealed to be a rare outcome in patient cohort, with frequency of 133 (0.82%) from outpatient file. Incidence of relapse to mania within 6 weeks of pharmacological treatment in the patient cohort came out to be 27 (0.17%) from hospital visits and 809 (5.01%) from office visits. Relapse to depression episode anytime post pharmacotherapy was suggested to be common, with 692 (4.28%) inpatient and 11,380 (70.46%) outpatient visitors. CONCLUSIONS: Given current treatment guideline for pediatric bipolar disorder does not have any recommendation for bipolar depression, future study is necessary to examine comparative effectiveness of existing pharmacotherapies used in children and adolescents with bipolar depression. 
PMH2 EVALUATING OUTCOMES FROM PRENATAL ANTIDEPRESSANT EXPOSURE: A META-ANALYTIC REVIEW
OBJECTIVES:
To summarize the literature regarding pregnancy/birth/child development outcomes of prenatal antidepressant exposure (PAE). METHODS: A Medline search was conducted up to October, 2011, restricted to English and human literature. The MeSH term "antidepressive agents", was combined with MeSH terms for spontaneous abortion(SA), preterm birth(PB), birth weight(BW), small for gestational age(SGA), or poor child development(PCD). We also searched articles from reference lists of reviews and included studies. We limited the review to studies with data analysis focusing on the impact of PAE on the outcomes listed above. Cochran's Q statistic was used to test the heterogeneity of the results of included studies for each outcome. When heterogeneity was absent, a fixed-effects model was used to pool the effect estimates. Otherwise, meta-regression was performed to explore the reasons for the observed heterogeneity. Meta-regression is a regression analysis in which each study is a unit of observation and the effect estimate is regressed on study characteristics. In this review, study characteristics including antidepressant class, type of source population, adjustment for maternal depression, exposure definition, duration and timing, and adjustment for more than three covariates were examined. RESULTS: Thirty-three studies were included (18 on PB, 9 on SA, 19 on BW). SGA and PCD were excluded from analysis due to the limited number of studies(nϽ6). The test of heterogeneity was significant for PB and meta-regression showed that adjusting for more than three covariates was significantly associated with the reported odds ratio(pϭ0.02). The pooled odds ratio(POR) for PB was 1.39 (95% confidence interval (CI)ϭ1.27-1.52) for studies with 3 covariates versus 1.82(95% CIϭ1.43-2.29) for other studies. The POR for SA was 1.63(95% CIϭ1.31-2.04) and the pooled difference in BW between the exposed and the unexposed was -23.6(95% CIϭ-50.1, 2.9) gram. CONCLUSIONS: The PORs showed that PAE was associated with PB and SA, but not BW. A unit of increase in CCI was associated with a 14% higher hazard of MDD incidence (pϽ0.01). CONCLUSIONS: The likelihood of MDD occurrence in acne patients treated with drug therapy varied with age and race. Consultation with dermatologists, family physicians, or pediatricians was associated with a lower hazard of MDD. Drug treatment of acne with isotretinoin, oral antibiotics, or topical antibiotics was associated with a reduced incidence of secondary MDD in acne patients, indicating that the treatment of the primary cutaneous indication may reduce the risk of secondary psychiatric comorbidities.
PMH3 ACNE DRUG THERAPY AND THE DEVELOPMENT OF COMORBID MAJOR DEPRESSIVE DISORDER IN THE UNITED STATES
PMH4 COMPARISON OF RISK ADJUSTMENT METHODS IN PREDICTING HEALTH CARE EXPENDITURE AMONG CHILDREN WITH ATTENTION DEFICIT/ HYPERACTIVITY DISORDER
